Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 69 of 80681 for:    measured

Atrial Fibrillation Cycle Length Measured on Transesophageal Echocardiography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03496272
Recruitment Status : Recruiting
First Posted : April 12, 2018
Last Update Posted : April 12, 2018
Sponsor:
Information provided by (Responsible Party):
Yong Hyun Park, Pusan National University Yangsan Hospital

Brief Summary:

Background: The atrial fibrillation cycle length (AFCL) measured by electrophysiologic study is well known parameter for the maintenance of sinus rhythm after DC cardioversion (DCCV) or ablation therapy. The aim of this study was to test whether a AFCL measured by transesophageal echocardiography (AFCLTEE) could predict the outcome after DCCV.

Methods: In 100 consecutive patients with non-valvular AF, TEE will be performed within 6 hours before DCCV. The AFCLTEE was measured by averaging 10 sequential peak to peak intervals of atrial fibrillary waves seen in the pulsed wave Doppler image on the left atrial appendage. The primary endpoint was AF free survival rate at 6 months after DCCV.


Condition or disease
Atrial Fibrillation

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: Atrial Fibrillation (AF) Cycle Length Measured on Transesophageal Echocardiography : a Feasible Parameter for Predicting the Recurrence of AF in Patients With AF Converted to Sinus Rhythm After DC Cardioversion
Actual Study Start Date : January 1, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. AF free survival rate at 6 months after DCCV [ Time Frame: 6 month ]
    Atrial fibrillation free state at 6 months after direct current cardioversion



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with non-valvular atrial fibrillation
Criteria

Inclusion Criteria:

  • atrial fibrillation

Exclusion Criteria:

  • moderate or severe mitral stenosis
  • prosthetic heart valve

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03496272


Contacts
Layout table for location contacts
Contact: Yong Hyun Park, MD 82-55-360-2363 nadroj@pusan.ac.kr

Locations
Layout table for location information
Korea, Republic of
Pusan National University Yangsan Hospital Recruiting
Yangsan, Korea, Republic of, 50612
Contact: Yong Hyun Park, MD         
Sponsors and Collaborators
Pusan National University Yangsan Hospital

Layout table for additonal information
Responsible Party: Yong Hyun Park, Associate Professor, Pusan National University Yangsan Hospital
ClinicalTrials.gov Identifier: NCT03496272     History of Changes
Other Study ID Numbers: PNUYH-IRB-05-2016-154
First Posted: April 12, 2018    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: April 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes